ivns1abpb Antibody

What is IVNS1ABP and what cellular functions is it involved in?

IVNS1ABP, also known as Nd1, is a multifunctional protein belonging to the Kelch family that plays crucial roles in several cellular processes. The protein is involved in pre-mRNA splicing, the aryl hydrocarbon receptor (AHR) pathway, F-actin organization, and protein ubiquitination. Additionally, it may play a significant role in mRNA nuclear export .

IVNS1ABP functions centrally in actin cytoskeleton dynamics through two primary mechanisms: direct association with F-actin and protection against actin derangement. Both the short (Nd1-S) and long (Nd1-L) isoforms cross-link actin filaments and protect against actin derangement, contributing to fundamental cellular functions including cell division, locomotion, and phagocytosis .

Research demonstrates that IVNS1ABP is a critical regulator of macrophage phenotype and function, particularly under inflammatory conditions. Modulation of the Ivns1abp gene in macrophages can modify their resistance to inflammation while maintaining functional phagocytosis .

What are the molecular characteristics of IVNS1ABP?

IVNS1ABP has distinct molecular characteristics that researchers should be aware of when designing experiments:

The protein contains Kelch repeats that mediate its association with F-actin, which is critical for its function in cytoskeletal organization . Understanding these characteristics is essential for correctly identifying IVNS1ABP in experimental results and interpreting data accurately.

Which species show reactivity with IVNS1ABP antibodies?

IVNS1ABP antibodies show reactivity across several species, which is important to consider when selecting antibodies for cross-species research:

When planning experiments with different model organisms, researchers should verify the cross-reactivity of their chosen IVNS1ABP antibody. Some antibodies may have broader reactivity than initially tested, potentially enabling comparative studies across species .

How does IVNS1ABP modulate macrophage function during inflammatory responses?

IVNS1ABP plays a critical role in preserving and promoting a reparative macrophage phenotype during inflammatory conditions. Research has demonstrated that:

• Inflammatory insults inhibit the Ivns1abp gene, which leads to inhibition of phagocytosis and compromises the ability of macrophages to induce proliferation and repair of damaged cells

• Inflammatory conditions alter the activity of transcription factor c-myc, which directly modulates IVNS1ABP gene expression

• Overexpression of IVNS1ABP in macrophages can enhance their resistance to inflammatory environments and maintain functional phagocytosis

Experimental approaches to study this phenomenon include:

• Adenoviral vector-mediated overexpression of IVNS1ABP

• Gene silencing using sh-Ivns1abp

• Adoptive transfer of ex vivo-modified macrophages overexpressing IVNS1ABP

• Co-culture systems with epithelial cells to assess repair functions

These findings suggest that IVNS1ABP could be a potential therapeutic target for improving macrophage function in inflammatory diseases.

What are the optimal protocols for detecting IVNS1ABP in different tissue types?

Detection of IVNS1ABP across different tissue types requires optimization of protocols based on the specific tissue being examined:

For immunohistochemistry (IHC):

• Positive IHC detection has been confirmed in human kidney tissue, human heart tissue, and mouse kidney tissue

• Recommended dilution: 1:20-1:200

• Antigen retrieval: Use TE buffer pH 9.0; alternatively, citrate buffer pH 6.0 can be used

For Western Blotting (WB):

• Positive detection in mouse heart tissue, apoptosised HeLa cells, HEK-293 cells, HeLa cells, K-562 cells, and mouse ovary tissue

• Recommended dilution: 1:500-1:3000

• It is advisable to optimize the dilution for each specific cell or tissue type through titration experiments

For Immunoprecipitation (IP):

• Successful IP has been documented in mouse heart tissue

• Recommended usage: 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate

How does gene silencing of IVNS1ABP affect cellular phenotypes in macrophages?

Gene silencing of IVNS1ABP in macrophages reveals significant alterations in cellular phenotypes with important functional consequences:

• Macrophages with silenced IVNS1ABP (using sh-Ivns1abp) show diminished capacity to maintain cytoskeletal integrity during inflammatory challenges

• The phagocytic capacity of macrophages is significantly reduced following IVNS1ABP silencing, indicating its essential role in this key macrophage function

• The reparative functions of macrophages are compromised when IVNS1ABP is silenced, as demonstrated in co-culture experiments with epithelial cells

Methodological approach:

• Transduction medium containing DMEM(high glucose)/F12 + GlutaMax 2% FBS with poly-l-lysine and the silencing virus at MOI 100 for sh-Ivns1abp

• Incubation for 24 hours at 37°C in a CO₂ incubator

• Quantification of IVNS1ABP expression by real-time qRT-PCR at 24 hours post-transfection

These findings highlight the significance of IVNS1ABP in maintaining macrophage functional plasticity and response capabilities during inflammatory conditions.

Methodological Considerations

When designing experiments to investigate IVNS1ABP function in macrophages, several critical factors should be considered:

Cell-type selection:

• Bone marrow-derived macrophages (BMDMs) have been successfully used in IVNS1ABP studies

• Peripheral blood monocyte-derived macrophages can provide a human model system

Gene modulation approaches:

• For overexpression: Adenoviral vectors carrying IVNS1ABP cDNA at MOI 250 provide effective expression

• For silencing: sh-Ivns1abp at MOI 100 has been validated

Functional assays:

• Phagocytosis assays to assess macrophage function

• Scratch wound assays with NRK-52e cells to assess the reparative capacity of modified macrophages

• Co-culture systems with epithelial cells to evaluate paracrine effects

• In vivo adoptive transfer experiments to assess functional impacts in disease models

Controls:

• β-galactosidase or GFP-expressing vectors serve as appropriate controls for overexpression studies

• Non-targeting shRNA vectors should be used as controls for silencing experiments

Timeframes:

• Expression analysis: 24 hours post-transfection

• Functional assays: 24-48 hours following gene modulation

How can researchers validate the specificity of IVNS1ABP antibodies?

Validating antibody specificity is crucial for ensuring reliable experimental results. For IVNS1ABP antibodies, a comprehensive validation approach should include:

• Western blot analysis:

  • Verify the correct molecular weight (observed ~70 kDa, calculated 72 kDa)

  • Include positive controls such as mouse heart tissue, HeLa cells, or HEK-293 cells where expression has been confirmed

  • Include a negative control using IVNS1ABP-knockdown cell lysates

• Immunoprecipitation validation:

  • Perform reciprocal IP using different IVNS1ABP antibodies targeting distinct epitopes

  • Confirm co-precipitation of known interaction partners

• Immunohistochemistry controls:

  • Include known positive tissue controls (human kidney, human heart, mouse kidney)

  • Perform parallel staining with secondary antibody only

  • Compare staining patterns across multiple antibodies targeting different regions of IVNS1ABP

• Functional validation:

  • Correlate antibody staining patterns with functional outcomes following gene silencing or overexpression

  • Perform rescue experiments to confirm specificity of observed phenotypes

• Epitope mapping:

  • For antibodies with known epitope regions (e.g., AA 1-300), verify specificity against recombinant protein fragments

How should researchers interpret inconsistent results with IVNS1ABP antibodies across different cell types?

Inconsistent results when using IVNS1ABP antibodies across various cell types can stem from several biological and technical factors:

Biological factors:

• IVNS1ABP expression levels vary naturally across cell types, with notable detection in heart tissue, kidney tissue, and certain cell lines (HeLa, HEK-293, K-562)

• Post-translational modifications might affect epitope accessibility in different cellular contexts

• Alternative splicing may generate tissue-specific isoforms with varying antibody reactivity

Technical considerations:

• Cell/tissue-specific optimization is essential; the recommended dilution ranges (1:500-1:3000 for WB; 1:20-1:200 for IHC) should be titrated for each model system

• Different lysis buffers may affect protein extraction efficiency and epitope availability

• Antigen retrieval methods significantly impact IHC results; while TE buffer (pH 9.0) is generally recommended, citrate buffer (pH 6.0) may be preferable for certain tissues

Methodological approach to resolve inconsistencies:

• Validate antibody performance in your specific experimental system using positive and negative controls

• Test multiple antibodies targeting different regions of IVNS1ABP

• Confirm protein expression using complementary approaches (e.g., qRT-PCR, mass spectrometry)

• Consider normalizing to loading controls appropriate for the subcellular fraction being analyzed

What experimental approaches are recommended for studying IVNS1ABP in cytoskeletal dynamics?

Given IVNS1ABP's role in actin cytoskeleton dynamics, specialized experimental approaches are needed to investigate this function:

Live-cell imaging techniques:

• Fluorescently tagged IVNS1ABP constructs enable real-time visualization of its interactions with the cytoskeleton

• Dual-color imaging with labeled actin provides direct evidence of co-localization and functional interaction

Biochemical approaches:

• Actin co-sedimentation assays to quantify IVNS1ABP binding to F-actin

• Actin cross-linking assays to assess the ability of IVNS1ABP to stabilize actin networks

Functional cytoskeletal assays:

• Scratch wound assays have been successfully used to assess cytoskeletal-dependent migration in epithelial cells co-cultured with IVNS1ABP-modified macrophages

• Protocol: Seed 1×10⁵ NRK-52e cells in 24-well culture plates until 80% confluence, starve for 16 hours, create scratch with pipette tip, wash with PBS, and stimulate with conditioned medium for 24 hours

• Phagocytosis assays provide functional readouts of cytoskeletal integrity in macrophages

Molecular manipulation approaches:

• Domain-specific mutations to identify regions critical for actin binding

• Structure-function analysis using truncated constructs to isolate the contribution of Kelch repeats to cytoskeletal stabilization

Advanced microscopy:

• Super-resolution techniques (STORM, PALM) can resolve nanoscale organization of IVNS1ABP in relation to actin filaments

• FRET-based approaches can quantify direct protein-protein interactions with cytoskeletal components

How is the IVNS1ABP gene regulated at the transcriptional level?

Understanding the transcriptional regulation of IVNS1ABP is important for experimental design and interpretation:

• The IVNS1ABP gene promoter is directly regulated by the transcription factor c-myc

• Inflammatory insults alter c-myc activity, subsequently modulating IVNS1ABP expression

• This regulatory relationship provides a mechanistic link between inflammatory stimuli and cytoskeletal changes in macrophages

Experimental approaches to study transcriptional regulation:

• Promoter-reporter assays to quantify transcriptional activity under different conditions

• ChIP assays to confirm c-myc binding to the IVNS1ABP promoter

• Site-directed mutagenesis of putative c-myc binding sites to validate functional importance

• Analysis of IVNS1ABP expression following c-myc activation or inhibition

These approaches can help elucidate how inflammatory signals are translated into cytoskeletal alterations through transcriptional control of IVNS1ABP, potentially revealing new therapeutic targets for inflammatory conditions.

What are the emerging roles of IVNS1ABP in inflammatory disease models?

Current research suggests expanding roles for IVNS1ABP in various inflammatory disease contexts:

• Adoptive transfer of macrophages overexpressing IVNS1ABP has shown promising results in ischemia/reperfusion models, suggesting therapeutic potential in acute inflammatory conditions

• The demonstrated role of IVNS1ABP in maintaining macrophage phagocytic capacity suggests it may be important in resolution of inflammation and tissue repair

• IVNS1ABP's function in cytoskeletal dynamics may have implications for macrophage migration and tissue infiltration during inflammatory responses

Future research should investigate:

• The therapeutic potential of IVNS1ABP modulation in chronic inflammatory diseases

• The relationship between IVNS1ABP expression and macrophage polarization states

• Potential interactions between IVNS1ABP and inflammasome components

• Development of small molecule modulators of IVNS1ABP function for therapeutic applications

How can researchers design studies to investigate IVNS1ABP's role during viral infections?

Given IVNS1ABP's identification as an influenza virus NS1A binding protein, investigating its role during viral infections requires specialized experimental approaches:

In vitro infection models:

• Compare IVNS1ABP expression and localization in infected versus uninfected cells

• Use gene silencing or overexpression of IVNS1ABP followed by viral challenge to assess functional impacts on viral replication

Protein-protein interaction studies:

• Co-immunoprecipitation of IVNS1ABP with viral NS1A protein under various conditions

• Identification of the specific domains mediating IVNS1ABP-NS1A interaction

• Investigation of how this interaction affects IVNS1ABP's normal cellular functions

Functional readouts:

• Assess cytoskeletal changes in infected cells with modulated IVNS1ABP expression

• Evaluate impact on antiviral signaling pathways, particularly those that involve cytoskeletal remodeling

• Investigate effects on viral entry, replication, and budding processes

Clinical correlations:

• Analyze IVNS1ABP expression in patient samples during viral infections

• Correlate expression levels with disease severity and outcomes